1. Home
  2. VNDA vs BGT Comparison

VNDA vs BGT Comparison

Compare VNDA & BGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • BGT
  • Stock Information
  • Founded
  • VNDA 2002
  • BGT 2004
  • Country
  • VNDA United States
  • BGT United States
  • Employees
  • VNDA N/A
  • BGT N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • BGT Trusts Except Educational Religious and Charitable
  • Sector
  • VNDA Health Care
  • BGT Finance
  • Exchange
  • VNDA Nasdaq
  • BGT Nasdaq
  • Market Cap
  • VNDA 288.2M
  • BGT 322.6M
  • IPO Year
  • VNDA 2006
  • BGT N/A
  • Fundamental
  • Price
  • VNDA $4.76
  • BGT $12.52
  • Analyst Decision
  • VNDA Strong Buy
  • BGT
  • Analyst Count
  • VNDA 3
  • BGT 0
  • Target Price
  • VNDA $15.33
  • BGT N/A
  • AVG Volume (30 Days)
  • VNDA 455.3K
  • BGT 107.2K
  • Earning Date
  • VNDA 07-30-2025
  • BGT 01-01-0001
  • Dividend Yield
  • VNDA N/A
  • BGT 10.77%
  • EPS Growth
  • VNDA N/A
  • BGT N/A
  • EPS
  • VNDA N/A
  • BGT N/A
  • Revenue
  • VNDA $201,351,000.00
  • BGT N/A
  • Revenue This Year
  • VNDA $16.86
  • BGT N/A
  • Revenue Next Year
  • VNDA $39.78
  • BGT N/A
  • P/E Ratio
  • VNDA N/A
  • BGT N/A
  • Revenue Growth
  • VNDA 13.37
  • BGT N/A
  • 52 Week Low
  • VNDA $3.81
  • BGT $10.89
  • 52 Week High
  • VNDA $6.37
  • BGT $13.42
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 51.75
  • BGT 53.73
  • Support Level
  • VNDA $4.67
  • BGT $12.42
  • Resistance Level
  • VNDA $5.04
  • BGT $12.64
  • Average True Range (ATR)
  • VNDA 0.21
  • BGT 0.13
  • MACD
  • VNDA -0.01
  • BGT -0.01
  • Stochastic Oscillator
  • VNDA 51.35
  • BGT 51.02

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About BGT BlackRock Floating Rate Income Trust

Blackrock Floating Rate Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income. The company's secondary investment objective is to seek the preservation of capital. The Trust seeks to achieve its investment objectives by investing mainly, under normal conditions, at least 80% of its assets in floating and variable rate instruments of U.S. and non-U.S. issuers, including a substantial portion of its assets in floating and variable rate securities including senior secured floating rate loans made to corporate and other business entities.

Share on Social Networks: